This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

 

 

 

Welcome to the Global Hepatitis Website 

Esteemed Colleagues,

It is my pleasure to address all of you as the Chair of the International Advisory Committee (IAC) which organizes the ISVHLD-Global Hepatitis Summit every two years. The Global Hepatitis Summit (GHS) is a meeting dedicated to advancing science, understanding, prevention and elimination of viral hepatitis worldwide. The Summit is attended by 1,000 to 1,500 participants representing all aspects of viral hepatitis research and education and those associations and organizations and patients that are working to combat hepatitis on the ground. The meeting has a tradition of excellence in basic and clinical science of viral hepatitis. In addition, important advances made in the understanding, diagnosis, management, control and prevention of viral hepatitis have been first presented at the previous Global Hepatitis Summits.

For GHS 2018 Toronto, we assembled an outstanding Scientific Program Committee of world leaders to develop the highest quality scientific program. I invite you to subscribe to our content capture. It provides access to all speakers and presentations in a myriad of topics on viral hepatitis, including:

  • WHO Elimination Targets
  • New Biomarkers & Endpoints in HBV
  • Point of Care & Testing Development 
  • HBV Virology
  • HCV Treatment - Remaining Challenges 
  • HEV Pathogenesis & Treatment
  • Diagnosis and treatment of liver cancer

We are in the midst of planning another outstanding Summit for 2020 in Taiwan, bringing together the top professionals from various areas to present the best science in viral hepatitis and to implement a roadmap to hepatitis elimination globally. The theme will be Evolution and Revolution of Viral Hepatitis and Liver Disease.

As you can see, we have been very busy, and it is our hope that these activities continue to grow in the coming years and beyond. All GHS participants and support staff continue to go above and beyond and I owe them a tremendous debt of gratitude.

I shall close by saying that our best efforts are made when we collectively work together towards elimination. We look forward to seeing you in Taiwan in June 2020 where even more will be achieved.

Thank You,


Harry L.A. Janssen
IAC Chair